| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer
|
Shibahara, Daisuke
|
|
|
25 |
6 |
p. 581-586.e3
|
artikel
|
| 2 |
Clinicopathological Features and Survival Outcomes of Resected Lung Adenosquamous Carcinoma: Results From a Nationwide Japanese Registry Data
|
Hishida, Tomoyuki
|
|
|
25 |
6 |
p. 519-528.e3
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
25 |
6 |
p. A1
|
artikel
|
| 4 |
Factors Associated With Margin Positivity After Lung Resection Surgery
|
Rshaidat, Hamza
|
|
|
25 |
6 |
p. 560-566
|
artikel
|
| 5 |
Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
|
Muscolino, Paola
|
|
|
25 |
6 |
p. e262-e267
|
artikel
|
| 6 |
Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer
|
Minne, Rachel L.
|
|
|
25 |
6 |
p. 567-576.e1
|
artikel
|
| 7 |
Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non–Small-Cell Lung Cancer
|
Gandara, David R.
|
|
|
25 |
6 |
p. e252-e261.e4
|
artikel
|
| 8 |
Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched‐Pair Cohort Study Using a Nationwide Inpatient Database
|
Iwai, Chikako
|
|
|
25 |
6 |
p. e243-e251
|
artikel
|
| 9 |
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC
|
Reck, Martin
|
|
|
25 |
6 |
p. 587-593.e3
|
artikel
|
| 10 |
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer
|
Shah, Arpeet T.
|
|
|
25 |
6 |
p. 550-559
|
artikel
|
| 11 |
Patients' Preferences for Adjuvant Osimertinib in Non–Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?
|
Awidi, Muhammad
|
|
|
25 |
6 |
p. 509-518
|
artikel
|
| 12 |
Prediction of Pleural Lavage Cytology According to Thin-Section Computed Tomography in Non–Small-Cell Lung Cancer
|
Nonaka, Yuto
|
|
|
25 |
6 |
p. 529-536
|
artikel
|
| 13 |
Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer
|
Keltner, Samuel
|
|
|
25 |
6 |
p. e268-e276.e1
|
artikel
|
| 14 |
Surgery and Stereotactic Radiotherapy for Stage I Small-Cell Lung Carcinoma: A 25-Year Experience
|
Robinson, Lary A.
|
|
|
25 |
6 |
p. 537-549.e2
|
artikel
|
| 15 |
Table of Contents
|
|
|
|
25 |
6 |
p. A3-A5
|
artikel
|
| 16 |
Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report
|
Kleemiss, Moritz
|
|
|
25 |
6 |
p. 577-580
|
artikel
|
| 17 |
The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases
|
Wu, Xiancheng
|
|
|
25 |
6 |
p. 483-501
|
artikel
|
| 18 |
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
|
Velcheti, Vamsidhar
|
|
|
25 |
6 |
p. 502-508.e3
|
artikel
|
Tijdschrift beschrijving